account_id none on file
legal_name Relmada Therapeutics, Inc.
ticker RLMD
cik 1553643
domain relmada.com
linkedin_company_url https://www.linkedin.com/company/relmada-therapeutics-inc
entry_point_account_id none on file
name Relmada Therapeutics Inc.
exchange Nasdaq
sector Health Care
hq Coral Gables, FL, United States
sector index/company/sector/health-care/
calls 0 filings 6 executives 6 family 0
why_nownone on file
callsnone on file
filings
Procedural Cost = $7,000-$10,0005, 7
ir_statement / Aug 8, 2026 / receipt
$6.5B total annual cost (U.S.)10
ir_statement / Aug 8, 2026 / receipt
High incidence1
ir_statement / Aug 8, 2026 / receipt
High recurrence5
ir_statement / Aug 8, 2026 / receipt
Multiple treatment courses
ir_statement / Aug 8, 2026 / receipt
NMIBC Represents Multi-Billion Dollar Market Opportunity
ir_statement / Aug 8, 2026 / receipt
executives
| Charles J. Casamento | director | - | receipt |
| Charles S. Ence | Chief Financial Officer | - | receipt |
| Kulendiran Purushothaman | Principal Financial Officer | - | receipt |
| Michael Becker | Chief Financial Officer | - | receipt |
| Sandesh Seth | Chairman of the Board | - | receipt |
| Sergio Traversa | Interim Chief Financial Officer | - | receipt |
familynone on file
upcoming
changes
| 2020-01-10 | Chief Financial Officer, departed | sec_8k |
| 2019-07-29 | Chief Financial Officer, appointed | sec_8k |
| 2017-02-17 | Interim Chief Financial Officer, appointed | sec_8k |
| 2016-05-13 | Chief Financial Officer, appointed | sec_8k |
| 2015-12-31 | Principal Financial Officer, appointed | sec_8k |
| 2015-07-16 | Chairman of the Board, appointed | sec_8k |
| 2015-07-16 | director, appointed | sec_8k |
mcp_package_hint
slug relmada-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$